Home Blog Page 57

Global Investment Giants Managing Trillions of Dollars Head to New Asia Forum 2026

BlackRock, KKR, Brookfield, Oaktree and Franklin Templeton among leading global investment institutions represented at the Inaugural Edition of the New Asia Forum in Bali


JAKARTA, INDONESIA – Media OutReach Newswire – 3 November 2026 – Some of the world’s most prominent investment institutions are set to participate in the inaugural New Asia Forum (NAF) 2026, underscoring the growing strategic importance of Asia in global investment and the opportunities to deepen enduring capital partnerships across the region and beyond.

Global Investment Giants Managing Trillions of Dollars Head to New Asia Forum 2026

Executives from BlackRock’s Global Infrastructure Partners, KKR, Brookfield, Oaktree and Franklin Templeton, alongside other leading institutions, will join more than 100 speakers at the forum, which will take place on 3 and 4 December 2026 at The Mulia, Bali, Indonesia.

Spanning across infrastructure, private equity, real estate and global asset management, these institutions bring extensive international investment experience and access to significant pools of institutional capital. Their participation reflects the increasing importance of connecting Asia’s economic growth and industrial transformation with patient, long term investment, particularly in energy, digital connectivity and advanced industries.

Confirmed speakers from the global investment community include Will Brilliant, Partner at Global Infrastructure Partners and Head of Digital Infrastructure at BlackRock; David Luboff, Partner, Co-Head of Asia Pacific and Head of Asia Pacific Infrastructure at KKR; Andrew Burych, Managing Partner and Head of East Asia at Brookfield Real Estate Group; Roger Zhang, Managing Director and Co-Head of Asia at Oaktree; and Manraj S. Sekhon, Chief Investment Officer of Templeton Global Investments at Franklin Templeton.

Global business and technology leaders from Freeport-McMoRan, Jardine Matheson, AirAsia, Databricks, Archer Aviation and Honeywell will also be represented, bringing perspectives from industries shaping the region’s next phase of economic growth.

Asia Pacific accounts for close to 60% of global economic growth, yet significant opportunities remain to mobilize long term capital towards the region’s investment and development priorities. As global investors reassess capital allocation strategies amid shifting economic and geopolitical dynamics, Asia offers opportunities for diversification, new partnerships and sustained value creation.

The investment institutions represented at NAF collectively manage trillions of dollars across public and private markets. Their participation brings together global capital, policymakers and business leaders to forge partnerships and advance concrete investment opportunities across the region.

Pahala Nugraha Mansury, Managing Director of Global Relations & Communications at Danantara Indonesia, a founding partner of the New Asia Forum, emphasized the importance of moving beyond investment interest towards sustained institutional engagement and concrete partnerships.

“The participation of leading global investment institutions shows that global investors are paying closer attention to Asia. However, the real opportunity is not just attracting more capital, but building the right partnerships to turn the region’s potential into lasting investment.

“The New Asia Forum brings global investors, governments and industry to the same table, so that conversations become meaningful collaboration and opportunities. For Danantara Indonesia, it is about establishing Indonesia as a trusted, enduring partner for global capital,” said Pahala.

Beyond the investment community, NAF 2026 will convene senior government leaders, including H.E. Tshering Tobgay, Prime Minister of the Kingdom of Bhutan, and Sebastian Kurz, former Federal Chancellor of Austria.

Their participation reflects NAF’s broader ambition to connect capital with the industrial capabilities, technologies and strategic partnerships required to unlock new investment opportunities across Asia. The growing lineup follows the announcement earlier this month of NAF 2026’s ambition to help mobilize US$30 billion in investment across the New Asia region, with Danantara Indonesia serving as a founding partner.

Designed to move beyond dialogue, NAF 2026 will place particular emphasis on facilitating actionable investment opportunities and partnerships. The forum will feature targeted investor engagements, private roundtables and opportunities to connect international capital with selected investment propositions. The objective is to establish relationships and advance discussions that can be developed into concrete investment outcomes beyond the forum itself.

Held under the patronage of President Prabowo Subianto, NAF 2026 is expected to convene more than 1,000 participants, including senior government officials, global investors, sovereign investment institutions and business leaders, across more than 40 sessions. Further speaker announcements and program updates will be released ahead of the December gathering.

As a founding partner of the New Asia Forum, Danantara Indonesia views the forum as an important platform to advance its mandate of mobilizing long-term capital, building strategic global partnerships, and expanding investment capacity to support Indonesia’s economic transformation. By bringing together global investors, sovereign institutions, policymakers and industry leaders, NAF 2026 enables Danantara Indonesia to connect international capital and expertise with investment opportunities in Indonesia’s priority sectors, while strengthening Indonesia’s position as a trusted long-term investment partner in the region.

Hashtag: #NewAsiaForum #NAF

The issuer is solely responsible for the content of this announcement.

Bangladesh Health Delegation Visits LIVE4WELL

Nearly 40 Media Representatives and Health Officials Take Part in Exchange; Exploring Preventive Medicine Development and Collaboration Opportunities in Asia


HONG KONG SAR – Media OutReach Newswire – 3 November 2026 – The Bangladesh Health Delegation undertook a seven-day visit to China, with a study visit to LIVE4WELL, a Hong Kong innovative health management platform, as one of its key engagements. The delegation visited LIVE4WELL on October 28. Its members included nearly 40 journalists and editors from Bangladesh, along with officials from Bangladeshi health departments. Through company presentations, technical exchanges and hands-on smart health screening experiences, delegates gained insight into Hong Kong’s developments in preventive medicine, health management and innovative health technology, and explored the application of related services in different markets, as well as opportunities for collaboration.

LIVE4WELL welcomes Bangladesh Health Delegation for exchange on preventive medicine.
LIVE4WELL welcomes Bangladesh Health Delegation for exchange on preventive medicine.

The participating Bangladesh media included Daily Sun, BSS, BTV, Independent TV, Jamuna TV, Somoy TV, Channel24, Daily Kalbela and Daily Kaler Kantho. The visit offered the delegation insights from the perspectives of technology, services and user-experience into how LIVE4WELL integrates smart health assessments into everyday health management, while providing an opportunity for healthcare industry exchange between Bangladesh and Hong Kong.

Exploring AI Health Screening Through Hands-on Smart Health Assessment

LIVE4WELL representatives first introduced the company’s vision and health management services to the delegation, followed by presentations on its seven AI health screening devices and home-grown healthcare large language model, Medical LLM for Healthcare (MediLLM). The presentations explored how different types of health data can be integrated to support health risk interpretation and personalized health management. Dr. Russell CHAN, Co-founder and Chief Executive Officer of E-SENSE Innovation & Technology Limited, was also invited to attend and introduce Electrical Impedance Tomography (EIT) screening technology.

The question-and-answer session drew an enthusiastic response, with media representatives actively raising questions on assessment accuracy, user fees and service arrangements, and engaging in in-depth exchanges with Ms. Miranda WONG, Co-founder of LIVE4WELL, and Dr. Russell CHAN, on how innovative health technologies can address the needs of different markets. Several Bangladeshi media outlets subsequently conducted separate interviews with the two to learn more about LIVE4WELL’s health management philosophy and the application of related screening technologies.

Following the presentations and discussions, the delegation toured the LIVE4WELL Intelligent Health Assessment Centre. LIVE4WELL representatives explained the functions, operation and assessment process of each screening device one by one. Delegates then experienced the smart screenings first-hand, gaining an understanding of the entire service journey from health assessment to report interpretation.

Deepening Hong Kong–Bangladesh Exchange and Exploring Cross-Regional Cooperation Opportunities

Ms. Miranda WONG, Co-founder of LIVE4WELL, said, “The visit of the Bangladesh Health Delegation to China has given us a deeper understanding of local concerns about health screening, service affordability and health management, while also enabling Bangladeshi media and health sector representatives to see first-hand how health technology is applied in Hong Kong. When expanding into different markets, we first seek to understand local income levels and actual needs and then work with potential partners to study suitable service offerings, pricing and cooperation models, rather than simply adopting our Hong Kong service model. We hope to take this exchange as a starting point to stay connected with various sectors in Bangladesh, deepen our understanding of the local healthcare environment and the needs of the public, and explore future opportunities for exchange and cooperation.”

LIVE4WELL continues to study preventive medicine development, health management needs and market conditions across Asia, and actively engages with the healthcare, health technology, corporate and community sectors in each locality. By combining health education, technology application and local collaboration, the company seeks to explore service models that meet local needs and are sustainable. On the technology front, LIVE4WELL also hopes to gradually build, through the research and development of MediLLM, a health database that better reflects the characteristics of Asian populations. This work will be advanced step by step in line with research and validation progress, subject to appropriate data governance, privacy protection and applicable regulatory requirements.

High-resolution photos HERE
Hashtag: #LIVE4WELL #Healthcare #AI #預防醫學 #Preventivemedicine

The issuer is solely responsible for the content of this announcement.

About LIVE4WELL

LIVE4WELL is Hong Kong’s leading innovative health management platform and Asia’s first health ecosystem that integrates preventive healthcare, artificial intelligence, and behavioral incentives. Through combining a suite of international medical-grade health screening devices with its proprietary AI motion capture technology, the platform delivers comprehensive dynamic health assessments and provides personalized health management solutions.

The platform’s flagship product, “VIV PASS,” revolutionizes health management by establishing personal health baselines, leveraging AI-powered health data analytics, delivering personalized exercise prescriptions, supplement recommendations and providing 24/7 health monitoring. LIVE4WELL innovatively combines health management with reward mechanisms through its Sweat Point system and WELLshop ecosystem, embodying the “Move to Earn” philosophy that transforms healthy behaviors into tangible rewards.

LIPSIA-STRATEGY trial demonstrates non-inferiority of CAAS vFFR guided revascularization against pressure wire-based FFR revascularization

  • LIPSIA-STRATEGY evaluated whether revascularization guided by angiography-based FFR using CAAS vFFR (vessel Fractional Flow Reserve), delivers clinical outcomes comparable to guidance by pressure wire-based FFR.
  • Conclusive trial results provide further randomized clinical evidence validating CAAS vFFR as a safe and effective alternative for wire-based physiology-guided revascularization.
  • Results independently confirm the findings of FAST III, demonstrating comparable clinical outcomes while enabling a faster, less invasive workflow with lower radiation exposure, ultimately benefiting both caregivers and patients.

MAASTRICHT, Netherlands, Nov. 3, 2026 /PRNewswire/ — Pie Medical Imaging, a global leader in cardiovascular image analysis solutions, announces the results of the LIPSIA-STRATEGY trial, presented during the Late-Breaking Clinical Trials session at the Transcatheter Cardiovascular Therapeutics (TCT) 2026 congress and simultaneously published in the Journal of the American College of Cardiology (JACC). The trial demonstrated non-inferiority of revascularization guided by angiography-derived CAAS vFFR compared with revascularization guided by conventional pressure wire-based FFR. 

LIPSIA-STRATEGY TRIAL
LIPSIA-STRATEGY TRIAL

LIPSIA-STRATEGY is an investigator-initiated, multicenter, randomized clinical trial involving 1,053 patients with intermediate coronary artery stenoses. The study was designed to evaluate whether coronary revascularization guided by angiography-derived CAAS vFFR could deliver clinical outcomes comparable to those achieved with conventional pressure wire-based FFR. Patients were randomized to either a vFFR-guided or FFR-guided treatment strategy, with 1-year major adverse cardiovascular events (MACE) serving as the primary endpoint. 

Under the leadership of Prof. Dr. med. Holger Thiele, Heart Center Leipzig at Leipzig University, together with the investigators and participating study centers, the trial successfully met its primary endpoint, demonstrating non-inferior clinical outcomes for the CAAS vFFR-guided treatment strategy. 

“Angiography-based FFR measurement is easier than wire-based FFR with similar clinical outcome. Thus, this should become the new standard for intermediate coronary artery stenoses.” Said Prof. Dr. med. Holger Thiele. 

Bas Kuppens, CEO of Pie Medical Imaging, added “LIPSIA-STRATEGY reinforces the findings of FAST III, adding to the clinical evidence for CAAS vFFR and further strengthening confidence in our angiography-based physiology solution. Together with a less invasive workflow, shorter procedure time and shorter fluoroscopy time, these results bring us another step closer to making physiology-guided decision-making more accessible across the PCI pathway, from diagnostic assessment and treatment planning to post-procedural evaluation. “

About Pie Medical Imaging

Pie Medical Imaging is a global leader in advanced cardiovascular image analysis, quantification and visualization. Based in Maastricht, The Netherlands, the company oversees worldwide innovation and commercialization of the CAAS and 3mensio product lines. With decades of expertise and deep commitment to innovation, Pie Medical Imaging delivers software solutions that empower clinicians, researchers, and industry partners to enhance diagnosis, procedure planning, and image‑guided interventions.

The company complies with international quality and regulatory standards, ensuring high reliability and clinical confidence.

Pie Medical Imaging is part of the Esaote Group, a leader in the biomedical equipment sector.

More information about Pie Medical Imaging is available at www.piemedicalimaging.com.

Convera accelerates global growth strategy with appointment of payments veteran Craig McDonald

Tasked with scaling strategic partnerships and channels to accelerate customer acquisition and revenue growth worldwide

SEATTLE and LONDON, Nov. 3, 2026 /PRNewswire/ — Convera, a global leader in commercial payments, today announced the appointment of Craig McDonald as Senior Vice President, Global Partnerships and Channels, joining the leadership team of Meaghan Riley, EVP and Chief Commercial Officer. McDonald will shape and scale Convera’s partner- and channel-led growth strategy, create new commercial models, and work with Product & Technology to prioritise and accelerate solutions to market.

Craig McDonald, SVP, Global Partnerships and Channels at Convera
Craig McDonald, SVP, Global Partnerships and Channels at Convera

The appointment follows the recent strengthening of Convera’s Product, Technology and Operations leadership under Mike Cahill, EVP and Chief Operating Officer. It extends the same focus on integrated execution to the partnerships and channels through which customers access Convera’s capabilities.

McDonald’s remit spans a broad set of markets and ecosystems, including software and embedded-payment partners, payroll and pension providers, financial institutions, fintechs, education, and other strategic partner channels. He will bring these opportunities together under a focused global strategy designed to deepen existing relationships and open new avenues for growth.

“Craig’s appointment is the next step in strengthening the leadership and execution behind Convera’s growth strategy,” said Meaghan Riley, EVP and Chief Commercial Officer at Convera. “Our partners and channels extend our reach into markets and customer relationships where Convera’s global payments network, FX expertise, and regulatory infrastructure can create real value. Craig has a proven record of turning complex opportunities into scalable businesses. He will shape a more connected global strategy, develop new commercial models, and work across our commercial and technology teams to bring solutions to market with greater focus and pace.”

McDonald has more than 20 years’ experience growing payments, fintech, and software-as-a-service businesses. Most recently he served as Chief Revenue Officer at global identity verification company Trulioo. Previously, at Trustly, he built from scratch the North American business to close to $200 million in revenue, building a team of around 140 people across sales, business development, account management, marketing, implementation, and customer success.

Earlier in his career, McDonald lived and worked in Prague, Warsaw, and Moscow, gaining extensive experience in cross-border markets across Central and Eastern Europe.

“Convera has a differentiated opportunity to help partners solve more of the complexity of moving and managing money across borders,” said Craig McDonald, SVP Global Partnership and Channels, Convera. “The foundation is strong: trusted relationships, global reach, and teams with deep expertise. I’m looking forward to working across the business to build scalable partner propositions, create new commercial models, accelerate solutions to market, and open new avenues for sustainable growth.”

 

About Convera

Convera is a global leader in commercial payments, helping businesses and institutions navigate the complexity of global commerce. It combines technology-led payment solutions with deep expertise in foreign exchange, risk management and compliance to help organizations manage cross-border payments with greater confidence. With an unrivalled regulatory footprint, a financial network spanning more than 140 currencies and 200 countries and territories, and nearly $200 billion in annual payment flows, Convera helps organizations move money globally with greater control, certainty and trust.

140th Canton Fair: Guochao Style Finds New Expressions in Fashion

GUANGZHOU, China, Nov. 3, 2026 /PRNewswire/ — What defines “Guochao,” or China-chic, today? At a themed release event on “Guochao Fashion” during Phase 3 of the 140th Canton Fair, exhibitors offered diverse answers, illustrating how Chinese cultural heritage can be reinterpreted through materials, craftsmanship and contemporary design.

Canton Fair
Canton Fair

Heritage Woven into Contemporary Fabrics

One of the highlights was a collection featuring Shu Brocade, the renowned silk jacquard textile from Sichuan and one of China’s four great brocades. Products showcasing original patterns inspired by centuries of cultural heritage attracted attention from visitors who photographed the intricate details. By blending traditional weaving techniques with modern aesthetics, the collection revitalizes an intangible cultural heritage craft while connecting it to today’s fashion market.

Another approach combined traditional Chinese ramie fabrics with the beauty of Chinese colors. Known for its natural texture and understated elegance, ramie has long been valued for its lightness and breathability. Through innovative dyeing techniques, designers infused these natural fibers with a rich palette inspired by Chinese culture, creating garments that balance simplicity, fluidity and contemporary style. The resulting collection presents a fresh and lightweight interpretation of Eastern aesthetics, bringing traditional cultural elements into today’s wardrobes.

Reimagining Tradition Through Design

Beyond fabrics, designers explored how fashion design itself can convey cultural narratives.

One featured collection drew inspiration from traditional Chinese papercutting art and the vitality of nature. Layered fabrics, intricate cutout details and thoughtful tailoring reinterpret the formal language of papercutting, including its symmetry and continuity, through a contemporary lens. The designs celebrate the independence and individuality of modern women while preserving the enduring elegance of Chinese craftsmanship.

A handbag series inspired by the famed painting A Thousand Li of Rivers and Mountains offered yet another expression of Guochao style. The collection draws from the blue-and-green landscape imagery of the Northern Song masterpiece. By transforming classical artistic motifs into everyday fashion accessories, it allows consumers to carry a piece of Chinese cultural heritage wherever they go.

As Phase 3 of the 140th Canton Fair continues under the “Better Life” theme, these creations illustrate how tradition and innovation can coexist. Whether through heritage textiles or artistic reinterpretation, they reflect an evolving lifestyle where cultural confidence, creativity and quality come together to shape a better future.

For more convenient attendance, please click here for pre-registration:

https://buyer.cantonfair.org.cn/register/buyer/email?source_type=16

Differentia Bio Advances Human Digital Twins with AI-Driven Disease Modeling and Clinical Validation

From millions of molecular measurements to clinically supported therapeutic predictions, Differentia is building AI-powered disease environments for pharmaceutical R&D.

SAN FRANCISCO, Nov. 3, 2026 /PRNewswire/ — Differentia Bio, a developer of AI-powered human disease digital twins, today announced that therapeutic mechanisms identified by its disease modeling platform in 2023–2024 have since gained support from independent clinical evidence, including an FDA-approved treatment and emerging clinical findings.

The findings offer an early look at one of AI’s most ambitious frontiers: moving beyond designing molecules to predicting how treatments may perform in complex human diseases before clinical outcomes are known.

From AI Predictions to Independent Clinical Evidence

Beginning in 2023, Differentia presented its IgG4-RD modeling research at international conferences, including ACoP, PAGE and NBC, and publicly announced its autoimmune disease platform in August 2024.

The research identified B-cell-directed interventions and the IL-4/Th2 pathway as promising therapeutic strategies. Subsequent independent developments supported both directions:

  • April 2025 — FDA Approval: The FDA approved inebilizumab, a CD19-directed therapy, as the first treatment for IgG4-RD. Its pivotal Phase 3 trial demonstrated an 87% reduction in disease flare risk compared with placebo.
  • January 2026 — Independent Clinical Evidence: An early study of dupilumab, which blocks IL-4Rα signaling, reported clinical improvement and reduced IgG4 levels in four of five patients, with three achieving normalization.

Unlike retrospective AI benchmarks that use previously known outcomes, Differentia documented its therapeutic hypotheses before these later clinical developments. Broader prospective validation is still needed, but the findings show how mechanistic AI predictions can be checked against subsequent human clinical evidence.

From Millions of Molecular Measurements to the Mechanisms That Matter

Differentia’s AI begins working before biological data is collected. By combining AI, biological knowledge graphs and systems biology, the platform identifies the most informative biological questions, pathways and multi-omics measurements needed to understand disease. This enables a disease-first approach to experimental design, rather than simply extracting insights from whatever data happen to be available.

For IgG4-RD, Differentia integrated single-cell RNA sequencing, flow cytometry and multiplex cytokine profiling from the same patients. From tens of thousands of cells and millions of molecular measurements, the analysis narrowed to the biological mechanisms that matter most for treatment decisions, comprising more than 30 biological components and more than 100 mechanistic interactions.

The selection process was itself consequential. While B-cell and IL-4/Th2 pathways emerged as promising intervention strategies, mechanisms pursued in certain unsuccessful clinical programs, including SLAMF7, were not identified as major disease drivers and therefore were not incorporated into the original model.

Their omission highlights the potential of AI-guided biological analysis to focus pharmaceutical development on the most consequential disease mechanisms with highest probability of success.

Beyond Drug Discovery: Custom-Built AI Disease Environments

Differentia’s proprietary DHARMA™ AI Disease Digital Twin Engine integrates generative AI, biological knowledge graphs, public scientific and clinical evidence, and deeply characterized patient-derived multi-omics data obtained through its global academic and clinical research collaborations. By combining real human disease biology with quantitative mechanistic modeling, Differentia builds multiscale disease digital twins that capture complex biological interactions and patient heterogeneity—providing a foundation for more predictive and clinically relevant simulations.

For pharmaceutical clients, Differentia incorporates asset-specific historical preclinical and clinical data to calibrate models and generate prospective predictions. As new client-specific clinical data become available, Differentia can incorporate these observations to recalibrate disease models and generate updated predictions for subsequent development decisions. The company also develops custom-built disease environments tailored to clients’ therapeutic areas and research programs, so internal R&D teams can run virtual experiments, compare therapeutic strategies and optimize clinical development decisions.

Across oncology, autoimmune and metabolic diseases, and different treatment modalities, Differentia aims to turn fragmented biological evidence into reusable decision intelligence—helping developers simulate patient populations, dosing strategies, indications and treatment combinations before committing resources to clinical trials.

The approach aligns with the growing regulatory adoption of Model-Informed Drug Development, including the finalization of ICH M15 and its implementation across major regulatory markets in 2026.

Turning Human Disease Intelligence Into Commercial Value

Differentia combines scientific leadership in AI, computational immunology, systems biology, quantitative pharmacology and clinical development with extensive pharmaceutical industry experience.

The company has established commercial relationships with multiple top-10 multinational pharmaceutical companies, biotechnology developers, clinical research organizations and investment institutions.

Through simulation-driven decision support and enterprise disease environments, Differentia aims to make predictive modeling a continuous capability throughout pharmaceutical R&D.

The ability to predict therapeutic outcomes before clinical trials will fundamentally change the economics of drug development. By identifying more promising disease mechanisms, optimizing clinical trial strategies and improving the probability of success (PoS), Differentia aims to reduce avoidable costly failures, accelerate development timelines and significantly increase pharmaceutical R&D return on investment (ROI).

The next frontier of AI drug development may not be discovering more molecules, but understanding human disease well enough to know which ones deserve to become medicines.

Simulate in virtual patients. Validate in real clinical trials.

About Differentia Bio

Differentia Bio is a San Francisco-based life sciences technology company developing AI-powered mechanistic digital twins and decision intelligence solutions for pharmaceutical R&D. Its proprietary DHARMA™ platform integrates AI, patient multi-omics, systems biology and quantitative pharmacology to simulate human disease and therapeutic responses. Differentia provides clinical development decision support and custom-built disease simulation environments, helping organizations make better R&D decisions before committing real-world time, capital and patients.

For more information, visit www.differentiabio.com.

Bridge Data Centres Appoints New Co-Chief Executive Officer

  • Mr Drew Chen’s appointment as Co-CEO strengthens BDC’s leadership team as the Company surpasses one gigawatt of capacity in 2026 and accelerates its growth across Asia Pacific.


SINGAPORE – Media OutReach Newswire – 3 November 2026 – Bridge Data Centres (BDC) is pleased to announce
the appointment of Mr Drew Chen as Co-Chief Executive Officer (Co-CEO), effective 1 November 2026. He will work alongside Mr Eric Fan, BDC’s Co-CEO, as a key member of the leadership team to accelerate the Company’s growth across Asia Pacific and beyond.

Mr Drew Chen, Co CEO of Bridge Data Centres
Mr Drew Chen, Co CEO of Bridge Data Centres

Mr Chen brings over 20 years of private equity experience, with a focus on the telecommunications, media, technology, and business services sectors. He previously served as a Senior Partner at Bain Capital and was a founding member of the firm’s Asia Pacific private equity team. Prior to Bain Capital, Mr Chen worked at Bain & Company. He holds a bachelor’s degree in economics from Harvard University and an MBA from Harvard Business School.

Mr Eric Fan, Co-CEO of Bridge Data Centres, said, “On behalf of Bridge Data Centres, we would like to welcome Drew. His appointment strengthens our leadership team at an important point in BDC’s growth, as we surpass one gigawatt of capacity in 2026. Drew’s experience and deep domain knowledge of the data centre sector will support our strategy as we scale BDC into a multi-gigawatt digital infrastructure platform in the coming years.”
Mr Drew Chen, Co-CEO of Bridge Data Centres, said, “The Asia Pacific data centre sector is at inflection point for growth, fuelled by surging cloud adoption and the rapid expansion of AI workloads. BDC is well positioned to capture this opportunity, backed by our world class engineering and design team, longstanding partnerships with global clients, and a decade of experience developing and operating next-generation digital infrastructure. I am excited to partner with Eric and the leadership team to scale BDC’s footprint across Asia Pacific and support our customers’ ambitious growth plans.”
Mr Jonathan Zhu, Partner and Chair of China at Bain Capital, said, “Drew possesses deep expertise in the digital infrastructure space and an intimate knowledge of BDC’s business, having played a pivotal role in the buildout of BDC and its sister company ChinData. We are delighted that, as the Co-CEO, Drew will continue to bring strategic foresight and robust business building capabilities to BDC. Together, he and Eric are well positioned to lead BDC through its next chapter of growth.”
Headquartered in Singapore, BDC is one of Asia Pacific’s top three next-generation digital infrastructure platforms by live capacity, with a presence across Malaysia, Thailand, Singapore, and India.

Hashtag: #BridgeDataCentres


The issuer is solely responsible for the content of this announcement.

About Bridge Data Centres

Bridge Data Centres (BDC) is a Singapore headquartered digital infrastructure platform delivering next-generation data centres across Asia Pacific and beyond.
Backed by Bain Capital, BDC operates in Malaysia, Thailand, India, and other high-growth markets, with an ambition to scale into a multi-gigawatt digital infrastructure platform in the near future.

Muddy Nam Song River Raises Public Doubts Over Official Explanation

A picture of Muddy water during the mid October to early November 2026 (Photo by Laophattana News)

Vang Vieng’s Nam Song River has been muddy for weeks, but many residents are questioning the authorities’ explanation for the change in water color.

People first reported the issue in October, saying the river had turned muddy even though there had been no rain. The water remained discoloured through 3 November.

At a meeting on 26 October, authorities agreed to investigate and called for action to clean up the river. They also discussed suspending projects that release sediment into the water to protect public trust and Vang Vieng’s tourism industry.

A week later, on 3 November, the Vang Vieng Commission for Information and Education said heavy rain in the northern Xaysomboun area had washed soil into three streams that flow down into the Nam Song. It also blamed land clearing for a new access road to Houay Khai waterfall in Vang Vieng.

Skepticism

The explanation has not convinced everyone. Residents, business owners, and travellers have pointed out that the river was already muddy for weeks before the recent rainfall.

“It’s been muddy for weeks without a drop of rain. Who are they trying to fool?” one commenter wrote. Another said the water had turned reddish-brown well before the rain arrived.

Some residents suspect that gold mining upstream may also be contributing to the problem. “Go check the gold mining sites near upstream, the water is completely polluted there,” one resident wrote in the comment section of a Facebook post by local media Laophattana News, raising concerns about possible damage to nearby farmland.

The comments bring back concerns about earlier pollution cases in the area. In July, authorities suspended Daochalearn Mineral Processing over river pollution following unauthorized upstream operations.

Concerns for Vang Vieng Tourism

The muddy water has also prompted concerns about the impact on local businesses. Vang Vieng attracts visitors for its rivers, limestone mountains, and outdoor activities, and residents worry that the discoloured water could put tourists off.

“Looking at water this color completely ruins the urge to travel. Vang Vieng is going to suffer massive income losses if this isn’t fixed immediately,” one social media user commented on the Facebook post.

Some residents are now calling for on-site inspections and clear evidence showing where the sediment is coming from.